Peptide Laboratory Practice
Peptide Deletion Sequence Impurities by LC-MS
Trace peptide deletions to failed coupling, deprotection, capping, or DKP formation using full-window HPLC, accurate mass, and diagnostic MS/MS evidence.
An n−1 impurity is not one compound. In a 30-residue synthesis, the term can describe many sequences, each missing a different amino acid. Their masses, retention, ionization, and abundance differ. A supplier who reports “n−1 below 0.2%” from one unidentified peak has probably simplified a much more complicated impurity family.
Deletion sequences arise when a coupling is incomplete and the unreacted chain remains available for later elongation. Effective capping can terminate that chain, making a predictable truncated impurity. Incomplete capping allows it to continue and produces a full-length-like sequence missing one residue. Deprotection failures, resin aggregation, reagent delivery problems, and local sequence effects create related routes.
Double deletions can form through repeated coupling failures or sequence-specific chemistry. Tirzepatide process research has described diketopiperazine-related double-amino-acid deletion impurities around susceptible proline-containing intermediates. That mechanism cannot be copied to every peptide, but it shows why a mass deficit needs a synthesis-based explanation.
Build a theoretical impurity list before the run
Start from the exact sequence, protecting-group strategy, resin, coupling order, and modifications. Calculate expected masses for single deletions at each position, likely truncations, incomplete side-chain modifications, and known rearrangements. Leucine and isoleucine deletions share the same mass. Repeated residues can produce different positional deletions with identical mass.
The list guides extracted-ion chromatograms but should not turn every matching signal into a confirmed identity. Mass tolerance, isotope fit, charge states, retention, and MS/MS must agree. Adducts and in-source fragments can imitate low-level deletion ions.
Use the raw multiply charged spectrum. Automated deconvolution may merge a weak impurity into the parent envelope or assign a wrong neutral mass. Dilute an overloaded sample and repeat. Minor species sometimes become easier to interpret when the dominant parent no longer suppresses them.
HPLC integration can hide deletion products
Shorter or less hydrophobic sequences may elute near the solvent front. A chromatogram cropped after two minutes excludes them by design. Other deletions coelute with the parent because loss of one residue produces little retention change. Full-window integration, orthogonal selectivity, and MS detection are needed.
Detector response also differs. A deletion that removes tryptophan, tyrosine, or phenylalanine will not share the parent’s UV response at every wavelength. Area percent is therefore not guaranteed to equal mass percent. Relative response factors or a justified estimate should be disclosed for specified impurities.
Collecting a suspect peak and reinjecting it can improve structural work, but preparative handling may change the sample. Record recovery and avoid claiming quantitative purity from a fraction that lost coeluting material.
Investigation checklist
- Complete sequence, residue numbering, modifications, resin, coupling, deprotection, and capping records.
- Theoretical single- and double-deletion masses with positional ambiguity clearly marked.
- Full HPLC acquisition window, raw integration, suitable wavelength, and orthogonal selectivity where needed.
- Accurate-mass extracted-ion traces, isotope patterns, charge states, and diagnostic MS/MS fragments.
- Review of in-process deprotection or coupling signals and reagent-delivery deviations.
- Synthesis or spike confirmation for critical named impurities when feasible.
Connect the impurity to the process
A mass match becomes more credible when the manufacturing record shows a difficult coupling at the same residue. Flow-SPPS research has linked sequence-dependent aggregation with changed deprotection profiles and difficult couplings. Conventional batch synthesis may not provide the same inline data, but resin sampling, coupling tests, and repeat-coupling history remain useful.
Trend the impurity across crude, purified, exchanged, and final material. A deletion already present in crude peptide is process-related. A peak that grows only during storage may be a degradation product with the same nominal deficit. Do not assign origin from final-lot data alone.
Purification can enrich an impurity relative to the parent when their solubility or recovery differs. A highly pure final fraction is not proof that the synthesis ran cleanly; it may reflect aggressive purification with poor yield. Procurement teams should examine both purity and process yield when consistency matters.
Supplier documentation and release
Ask for specified deletion sequences by structure, not generic n−1 labels. The COA should state which impurities are identified, which are tentatively assigned, and which remain unknown. A single total-impurity limit may be sufficient for low-risk RUO work, but reference materials and sensitive assays need stronger characterization.
Retain raw LC-MS data and processing methods. Software libraries improve, and a future investigation may reinterpret a low-level feature. Reprocessing should be version-controlled rather than replacing the original result.
Separate deletion impurities from other synthesis errors
Not every mass deficit is a missing residue. Incomplete protecting-group removal, dehydration, cyclization, and fragmentation can generate related shifts. Epimerization produces no mass change at all. A deletion search therefore belongs inside a broader impurity workflow rather than replacing it.
Compare observed mass differences with exact residue masses and likely chemistry. Loss of water or ammonia may occur in the source, while a true deletion should be supported by sequence fragments spanning the missing position. For long peptides, complementary fragmentation or enzymatic maps improve coverage. If leucine and isoleucine are involved, ordinary MS/MS may not resolve the positional identity without additional evidence.
Capping efficiency also changes how an impurity appears. A capped failure chain may terminate early and elute far from the parent. An uncapped failure can continue to full length and closely resemble it. Review the capping reagent, exposure, and wash steps when the crude profile shifts.
Set reporting thresholds with method sensitivity in mind. “Not detected” should include the tested limit. A low-abundance extracted ion seen below the validated quantitation level can be documented as a trace signal without assigning a precise percentage.
Peptides Archive can review an RUO deletion-impurity map or help translate a synthesis record into targeted LC-MS checks. This article concerns manufacturing and analytical quality only; it provides no dosing, administration, or human-use guidance.
Primary records and verification routes
Use the primary paper, current regulator record, or lot-linked analytical file for the claim it supports. A search result is a route to evidence, not evidence itself.